法洛四联症修复后肺动脉瓣置换:生物瓣与机械瓣结局比较
该研究纳入2004至2017年131例已行法洛四联症或其变异型修复、首次接受机械瓣或生物瓣肺动脉瓣置换的患者,比较瓣膜失败与再干预结局。中位随访7.4年,10年生存率96.4%,生物瓣与机械瓣在瓣膜失败和再干预上差异无统计学意义,机械瓣未显示优越性。
要点
- 生物瓣与机械瓣10年瓣膜失败率分别为19.5%与34.8%,差异无统计学意义。
- 较小体表面积和较小瓣膜尺寸是瓣膜失败与再干预的危险因素。
- 机械瓣组有4例发生抗凝相关重大血栓栓塞事件,选择机械瓣需谨慎。
核心结论
- 机械瓣在瓣膜失败或再干预方面可能并不优于生物瓣。
- 在经导管肺动脉瓣置换时代,机械瓣应仅用于高度选择的患者。
研究设计与样本
- 回顾性比较研究,纳入2004至2017年131例已修复法洛四联症或其变异型、首次行肺动脉瓣置换的患者。
- 生物瓣组88例(67.2%),机械瓣组43例(32.8%),肺动脉瓣置换中位年龄19岁,中位随访7.4年。
主要发现
- 10年生存率为96.4%。
- 10年瓣膜失败概率为24.6%(生物瓣19.5% vs 机械瓣34.8%,P=0.34)。
- 10年再干预概率为7.8%(生物瓣5.6% vs 机械瓣11.9%,P=0.079)。
- 瓣膜失败危险因素为较小体表面积(每1 m2 HR 0.23,P=0.047)和较小瓣膜尺寸(每1 mm HR 0.73,P=0.039)。
- 再干预危险因素为较小体表面积(每1 m2 HR 0.11,P=0.011)和瓣膜尺寸(每1 mm HR 0.67,P=0.044)。
关键数值与推荐
- 瓣膜失败定义为狭窄>3.5 m/s、反流>轻度或感染性心内膜炎。
- 机械瓣组4例发生抗凝相关重大血栓栓塞事件。
临床怎么用
- 法洛四联症修复后首次肺动脉瓣置换选择瓣膜类型时,不应默认机械瓣优于生物瓣。
- 对体表面积小或需植入较小瓣膜的患者,应加强随访并警惕瓣膜失败与再干预风险。
局限性
- 原文摘要未报告研究局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aims of this study were to evaluate and compare the outcomes after pulmonary valve replacement (PVR) with a mechanical prosthesis (MP) and a bioprosthesis (BP). METHODS: From 2004 through 2017, a total of 131 patients, who had already been repaired for tetralogy or Fallot or its variants, underwent their first PVR with an MP or a BP. Outcomes of interests were prosthesis failure (stenosis >3.5 m/s, regurgitation >mild or infective endocarditis) and reintervention. RESULTS: The median age at PVR was 19 years. BP and MP were used in 88 (67.2%) and 43 (32.8%) patients, respectively. The median follow-up duration was 7.4 years, and the 10-year survival rate was 96.4%. Risk factors for prosthesis failure were smaller body surface area [hazard ratio (HR) 0.23 per 1 m2, P = 0.047] and smaller prosthesis size (HR 0.73 per 1 mm, P = 0.039). Risk factors for prosthesis reintervention were smaller body surface area (HR 0.11 per 1 m2, P = 0.011) and prosthesis size (HR 0.67 per 1 mm, P = 0.044). Probability of prosthesis failure and reintervention at 10 years were 24.6% (19.5% in BP vs 34.8% in MP, P = 0.34) and 7.8% (5.6% in BP vs 11.9% in MP, P = 0.079), respectively. Anticoagulation-related major thromboembolic events were observed in 4 patients receiving an MP. CONCLUSIONS: MP might not be superior to BP in terms of prosthesis failure or reintervention. MP should be carefully considered for highly selected patients in the era of transcatheter PVR.
引用
- Kim DH, Choi ES, Kwon BS, et al. Pulmonary valve replacement following repair of tetralogy of Fallot: comparison of outcomes between bio- and mechanical prostheses. Eur J Cardiothorac Surg. 2021. PMID: 33693501. doi:10.1093/ejcts/ezab099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。